ImmunityBio (IBRX) said Tuesday it completed submissions to the US Food and Drug Administration, including the supplemental biologics license application for ANKTIVA plus Bacillus Calmette-Guerin to treat BCG-unresponsive non-muscle invasive bladder cancer in papillary disease.
The company also submitted an expanded access protocol to the FDA to make ANKTIVA available for the treatment of lymphopenia, according to a statement.
ImmunityBio also reported preliminary net product revenue of about $16.5 million for Q1, up from $7.2 million in Q4.
Price: 2.91, Change: +0.02, Percent Change: +0.69
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.